Source: International Congress 2015 – Interstitial lung diseases I
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Inigo Ojanguren Arranz (Barcelona, Spain), Iñigo Ojanguren, Ana Villar, María Antonia Ramón, María Jesus Cruz, Xavier Muñoz, Ferran Morell. Rituximab for the treatment of chronic hypersensitivity pneumonitis. Eur Respir J 2015; 46: Suppl. 59, 815

Member's Comments

No comment yet.

Related content which might interest you: Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Rituximab therapy for interstitial lung disease in patients with antisynthetase syndrome Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Treatment response in hypersensitivity pneumonitis Source: International Congress 2016 – Orphan diseases II Year: 2016 Cyclophosphamide in steroid-refractory hypersensitivity pneumonitis and non-classifiable interstitial lung disease Source: International Congress 2017 – Novel and old entities Year: 2017 Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD Source: International Congress 2016 – Connective tissue disorders Year: 2016 Chronic hypersensitivity pneumonitis: Is the interstitial pneumonias disease behavior classification suitable for outcome stratification? Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Mortality and survival predictor in chronic hypersensitivity pneumonitis Source: International Congress 2016 – Sarcoidosis Year: 2016 Lymphangioma in patients with pulmonary lymphangioleiomyomatosis – Results of sirolimus treatment Source: International Congress 2016 – Orphan diseases I Year: 2016 Methotrexate (MTX) as a single agent for treating chronic, progressive sarcoidosis Source: International Congress 2014 – Sarcoidosis Year: 2014 Chronic hypersensitivity pneumonitis with familial history of interstitial lung disease Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010 Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Rituximab in severe, treatment-refractory interstitial lung disease Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 The efficacy of cyclosporine A in patients with clinicoradiologically diagnosed idiopathic nonspecific interstitial pneumonia Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Early detection of subclinical interstitial lung disease in patients with rheumatoid arthritis and effect of methotrexate therapy Source: International Congress 2014 – ILDs 4 Year: 2014 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Childhood diffuse parenchymal lung diseases: Diagnosis, treatment and outcome Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Childhood interstitial lung disease: A diagnostic challenge Source: International Congress 2015 – Connective tissue disorders Year: 2015